Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,597	$ 19,031
Prepaid expenses	276	83
Other current assets	686	28
Total current assets	11,559	19,142
Property, equipment and leasehold improvements, net	229	127
Restricted cash - non-current	150	150
Operating lease right-of-use assets	942	1,229
Prepaid clinical trial expenses	475	1,122
Total assets	13,355	21,770
Current liabilities:
Accounts payable	864	605
Operating lease liabilities	387	361
Accrued expenses	1,250	1,646
Total current liabilities	2,501	2,612
Other liabilities	102	94
Operating lease liabilities - non-current	656	949
Total liabilities	3,259	3,655
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.00001 par value, authorized 250,000,000 and 2,000,000 at September 30, 2022 and December 31, 2021, respectively. 1,391,160 and 1,370,595 shares issued and outstanding including Zero and 254 shares of unvested restricted stock awards, at September 30, 2022 and December 31, 2021, respectively.	3	3
Additional paid-in capital	256,351	256,241
Accumulated deficit	(246,258)	(238,129)
Total stockholders' equity	10,096	18,115
Total liabilities and stockholders' equity	$ 13,355	$ 21,770